Press releases

Eevia Health's share issue in connection to listing on Spotlight Stock Market over-subscribed over 400 percent

Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%).

The Offering comprised 3,445,000 shares in Eevia and the subscription price amounted to SEK 7.6 per share, meaning that the Company will receive gross proceeds of SEK 26.2 million, and after deduction of issue costs of SEK 2.2 million, net proceeds of SEK 24.0 million. Eevia has added approximately 700 new shareholders through the Offering. The first day of trading on Spotlight Stock Market is scheduled for June 29, 2021.

Stein Ulve, CEO and Founder Eevia Health comments:

"I am overwhelmed to see the great interest for investing in the growth of our company.This listing is an important step in our long-term journey of building Eevia Health. Today, I thank existing as well as new shareholders for the trust and for supporting us in making the world healthier. Unfortunately, we were not able to allocate shares to all subscribers - to those who did not receive allotment, I wish to welcome you to become shareholders on the 29th of June, when trading in Eevia Health commences on Spotlight Stock Market."

Following the completion of the Offering, the number of shares in Eevia Health increases from 10,506,500 to 13,961,500 corresponding to a dilution of approximately 24,7 percent. The Offering was covered by subscription commitments amounting to 58 percent of the issue volume, corresponding to SEK 15.2 million. Subscription commitments were entered into by Consensus Asset Management, Polynom Investment and Modelio Equity amongst others.

Advisors
Partner Fondkommission is financial advisor and issuing agent in Sweden in relation to the Offering. OP Bank is issuing agent in Finland in relation to the Offering.

For more information, please contact:
Stein Ulve, CEO
stein.ulve@eeviahealth.com
Tel.: +358 400 22 5967

Kim Nurmi-Aro, CFO
kim@eeviahealth.com
+358 504 44 0717

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 17, 2021.

About Eevia

Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive byproducts from food and woodindustries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.

Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January - 31st March, corresponding to 560 percent sales growth compared to the same period prior year.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE IN CONFLICT WITH APPLICABLE RULES OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS.

2021-08-13
Regulatory

The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1st through June 30th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com 

2021-08-05

Eevia Health Plc, ("Eevia" or "The Company"), has installed new capacities and automation equipment for processing and evaporation of natural plant extract liquids. As of August 1st, the newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.

2021-07-01

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.

2021-06-29

Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.

2021-06-22
Regulatory

The Annual General Meeting of shareholders of Eevia Health Plc was held in Seinäjoki, on June 22, 2021. Two shareholders representing 3 797 500 shares and votes (36,14% of total shares) were represented at the meeting. The AGM decided each and all the proposals from the Board of Directors as described in the Notice of Annual General Meeting, unanimously.

2021-06-17

This is a correction to earlier press release today, which stated that the equity issue was over-subscribed by over 400%. The correct is subscribed by over 400%. Also in one media channel the MAR label was omitted by mistake in the Press release itself.

Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%). 

2021-06-17
Regulatory

Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%).

1
2